Marc Y Donath

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3900675/publications.pdf

Version: 2024-02-01

102 papers	17,905 citations	43973 48 h-index	35952 97 g-index
107 all docs	107 docs citations	107 times ranked	20883 citing authors

#	Article	IF	Citations
1	Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology, 2011, 11, 98-107.	10.6	2,777
2	Interleukin-1â€“Receptor Antagonist in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2007, 356, 1517-1526.	13.9	1,579
3	Effect of interleukin-1Î² inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1833-1842.	6.3	948
4	Glucose-induced Î² cell production of IL-1Î² contributes to glucotoxicity in human pancreatic islets. Journal of Clinical Investigation, 2002, 110, 851-860.	3.9	938
5	Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nature Medicine, 2011, 17, 1481-1489.	15.2	714
6	Increased Number of Islet-Associated Macrophages in Type 2 Diabetes. Diabetes, 2007, 56, 2356-2370.	0.3	644
7	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, The, 2018, 391, 319-328.	6.3	628
8	Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature Reviews Drug Discovery, 2014, 13, 465-476.	21.5	571
9	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	7.0	506
10	Glucose-induced Î² cell production of IL-1Î² contributes to glucotoxicity in human pancreatic islets. Journal of Clinical Investigation, 2002, 110, 851-860.	3.9	491
11	Inflammation in obesity, diabetes, and related disorders. Immunity, 2022, 55, 31-55.	6.6	489
12	Mechanisms of Â-Cell Death in Type 2 Diabetes. Diabetes, 2005, 54, S108-S113.	0.3	397
13	Inflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes. Journal of Molecular Medicine, 2003, 81, 455-470.	1.7	379
14	Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes. Diabetes Care, 2009, 32, 1663-1668.	4.3	347
15	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, The, 2013, 381, 1905-1915.	6.3	301
16	Increased Interleukin (IL)-1Î² Messenger Ribonucleic Acid Expression in Î²-Cells of Individuals with Type 2 Diabetes and Regulation of IL-1Î² in Human Islets by Glucose and Autostimulation. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4065-4074.	1.8	290
17	Inflammation in Obesity and Diabetes: Islet Dysfunction and Therapeutic Opportunity. Cell Metabolism, 2013, 17, 860-872.	7.2	290
18	Islet Inflammation in Type 2 Diabetes. Diabetes Care, 2008, 31, S161-S164.	4.3	286

#	Article	IF	Citations
19	Postprandial macrophage-derived IL-1Î² stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nature Immunology, 2017, 18, 283-292.	7.0	286
20	Free Fatty Acids Induce a Proinflammatory Response in Islets via the Abundantly Expressed Interleukin-1 Receptor I. Endocrinology, 2009, 150, 5218-5229.	1.4	285
21	Islet Inflammation Impairs the Pancreatic Î²-Cell in Type 2 Diabetes. Physiology, 2009, 24, 325-331.	1.6	264
22	Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes. Diabetes Care, 2012, 35, 1654-1662.	4.3	237
23	Targeting innate immune mediators in type 1 and type 2 diabetes. Nature Reviews Immunology, 2019, 19, 734-746.	10.6	237
24	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the American College of Cardiology, 2018, 71, 2392-2401.	1.2	236
25	Leptin modulates Â cell expression of IL-1 receptor antagonist and release of IL-1Â in human islets. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8138-8143.	3.3	234
26	Interleukin-6 regulates pancreatic Î±-cell mass expansion. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13163-13168.	3.3	234
27	Cytokines and Î²-Cell Biology: from Concept to Clinical Translation. Endocrine Reviews, 2008, 29, 334-350.	8.9	201
28	Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia, 2010, 53, 1795-1806.	2.9	196
29	Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends in Endocrinology and Metabolism, 2010, 21, 261-267.	3.1	196
30	Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. Diabetes Care, 2016, 39, S244-S252.	4.3	189
31	Low Concentration of Interleukin-1Â Induces FLICE-Inhibitory Protein-Mediated Â-Cell Proliferation in Human Pancreatic Islets. Diabetes, 2006, 55, 2713-2722.	0.3	151
32	The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications. Trends in Endocrinology and Metabolism, 2015, 26, 551-563.	3.1	146
33	FLIP switches Fas-mediated glucose signaling in human pancreatic Â cells from apoptosis to cell replication. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8236-8241.	3.3	133
34	The Role of Inflammation in Î²-cell Dedifferentiation. Scientific Reports, 2017, 7, 6285.	1.6	130
35	Interleukin-33-Activated Islet-Resident Innate Lymphoid Cells Promote Insulin Secretion through Myeloid Cell Retinoic Acid Production. Immunity, 2017, 47, 928-942.e7.	6.6	123
36	Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes. Cell Metabolism, 2013, 17, 448-455.	7.2	103

#	Article	IF	Citations
37	Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia, 2016, 59, 679-682.	2.9	93
38	Pancreatic islet inflammation in type 2 diabetes: From Î± and Î² cell compensation to dysfunction. Archives of Physiology and Biochemistry, 2009, 115, 240-247.	1.0	87
39	Pancreatic Î± Cell-Derived Glucagon-Related Peptides Are Required for Î² Cell Adaptation and Glucose Homeostasis. Cell Reports, 2017, 18, 3192-3203.	2.9	87
40	The Fas pathway is involved in pancreatic beta cell secretory function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2861-2866.	3.3	83
41	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet, The, 2020, 396, 267-276.	6.3	78
42	Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease. Endocrine Reviews, 2019, 40, 1080-1091.	8.9	70
43	GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine?. Diabetes Care, 2013, 36, S145-S148.	4.3	66
44	Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets viaÂInterleukin 6, Produced by Î± Cells. Gastroenterology, 2016, 151, 165-179.	0.6	59
45	Î² Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs Î² Cell Proliferation and Insulin Secretion. Cell Reports, 2018, 22, 1774-1786.	2.9	59
46	Development of an Interleukin-1Î² Vaccine in Patients with Type 2 Diabetes. Molecular Therapy, 2016, 24, 1003-1012.	3.7	57
47	Characteristics of a multisensor system for non invasive glucose monitoring with external validation and prospective evaluation. Biosensors and Bioelectronics, 2011, 26, 3794-3800.	5.3	55
48	Inhibition of IL-1Â Improves Fatigue in Type 2 Diabetes. Diabetes Care, 2011, 34, e158-e158.	4.3	54
49	GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia, 2020, 63, 362-373.	2.9	48
50	Angiotensin II Induces Interleukin-1Î²â€“Mediated Islet Inflammation and Î²-Cell Dysfunction Independently of Vasoconstrictive Effects. Diabetes, 2015, 64, 1273-1283.	0.3	45
51	Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2014, 306, R861-R867.	0.9	44
52	IL-6â€“Type Cytokine Signaling in Adipocytes Induces Intestinal GLP-1 Secretion. Diabetes, 2018, 67, 36-45.	0.3	39
53	Distinct Transcriptional Responses across Tissue-Resident Macrophages to Short-Term and Long-Term Metabolic Challenge. Cell Reports, 2020, 30, 1627-1643.e7.	2.9	38
54	What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia, 2014, 57, 653-655.	2.9	36

#	Article	IF	Citations
55	Type 1, type 1.5, and type 2 diabetes: NOD the diabetes we thought it was. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12217-12218.	3.3	35
56	Susceptibility to Fatty Acid-Induced Î²-Cell Dysfunction Is Enhanced in Prediabetic Diabetes-Prone BioBreeding Rats: A Potential Link Between Î²-Cell Lipotoxicity and Islet Inflammation. Endocrinology, 2013, 154, 89-101.	1.4	34
57	Inflammation as a Sensor of Metabolic Stress in Obesity and Type 2 Diabetes. Endocrinology, 2011, 152, 4005-4006.	1.4	32
58	Fractalkine (CX3CL1), a new factor protecting Î²-cells against TNFÎ±. Molecular Metabolism, 2014, 3, 731-741.	3.0	31
59	Successful Treatment of Immune Checkpoint Inhibitorâ€“Induced Diabetes With Infliximab. Diabetes Care, 2019, 42, e153-e154.	4.3	29
60	Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1Î². Cell Metabolism, 2020, 31, 699-709.e5.	7.2	28
61	IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3466-3476.	1.8	27
62	Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes. Diabetes Care, 2013, 36, e90-e91.	4.3	25
63	First Experiences With a Wearable Multisensor Device in a Noninvasive Continuous Glucose Monitoring Study at Home, Part II: The Investigatorsâ€™ View. Journal of Diabetes Science and Technology, 2018, 12, 554-561.	1.3	23
64	Evidence for cephalic phase insulin release in humans: A systematic review and meta-analysis. Appetite, 2020, 155, 104792.	1.8	22
65	IL (Interleukin)-1 Receptor Antagonist Increases Ang (Angiotensin [1â€“7]) and Decreases Blood Pressure in Obese Individuals. Hypertension, 2020, 75, 1455-1463.	1.3	22
66	Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2015, 29, 955-960.	1.2	21
67	Interleukin-1 receptor antagonist: friend or foe to the heart?. Lancet Diabetes and Endocrinology,the, 2015, 3, 228-229.	5.5	21
68	The Effect of a Global, Subject, and Device-Specific Model on a Noninvasive Glucose Monitoring Multisensor System. Journal of Diabetes Science and Technology, 2015, 9, 865-872.	1.3	21
69	Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1712-1718.	1.8	20
70	Proteomic Landscape of Aldosterone-Producing Adenoma. Hypertension, 2019, 73, 469-480.	1.3	19
71	A role for interleukin-22 in the alleviation of metabolic syndrome. Nature Medicine, 2014, 20, 1379-1381.	15.2	17
72	Inhibition of IL-1beta improves Glycaemia in a Mouse Model for Gestational Diabetes. Scientific Reports, 2020, 10, 3035.	1.6	17

#	Article	IF	Citations
73	The cephalic phase of insulin release is modulated by IL-1Î². Cell Metabolism, 2022, 34, 991-1003.e6.	7.2	17
74	First Experiences With a Wearable Multisensor in an Outpatient Glucose Monitoring Study, Part I: The Usersâ€™ View. Journal of Diabetes Science and Technology, 2018, 12, 562-568.	1.3	14
75	Exercise upregulates copeptin levels which is not regulated by interleukin-1. PLoS ONE, 2019, 14, e0217800.	1.1	13
76	Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?. Cell Metabolism, 2021, 33, 2-4.	7.2	13
77	When metabolism met immunology. Nature Immunology, 2013, 14, 421-422.	7.0	12
78	IKKÎ² inhibition prevents fat-induced beta cell dysfunction in vitro and in vivo in rodents. Diabetologia, 2017, 60, 2021-2032.	2.9	12
79	Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetes. Diabetologia, 2015, 58, 425-428.	2.9	10
80	The role of IL-1 in postprandial fatigue. Molecular Metabolism, 2018, 12, 107-112.	3.0	10
81	IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis. Metabolites, 2021, 11, 79.	1.3	10
82	Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial. Endocrine Connections, 2019, 8, 701-708.	0.8	10
83	IL-1beta promotes the age-associated decline of beta cell function. IScience, 2021, 24, 103250.	1.9	10
84	IL-1Î² Activation as a Response to Metabolic Disturbances. Cell Metabolism, 2010, 12, 427-428.	7.2	9
85	Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes Therapy, 2021, 12, 943-954.	1.2	9
86	Muscle-Derived IL-6 Is Not Regulated by IL-1 during Exercise. A Double Blind, Placebo-Controlled, Randomized Crossover Study. PLoS ONE, 2015, 10, e0139662.	1.1	7
87	Treatment of Primary Aldosteronism With mTORC1 Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4703-4714.	1.8	7
88	Insulin-Like Growth Factor I. Drugs and Aging, 1999, 15, 251-254.	1.3	6
89	Multisensor Concept for non-invasive Physiological Monitoring. Conference Record - IEEE Instrumentation and Measurement Technology Conference, 2007, , .	0.0	6
90	Inflammation and type 2 diabetes: from basic science to treatment. Seminars in Immunopathology, 2019, 41, 411-412.	2.8	6

#	Article	IF	Citations
91	Model-Based Assessment of C-Peptide Secretion and Kinetics in Post Gastric Bypass Individuals Experiencing Postprandial Hyperinsulinemic Hypoglycemia. Frontiers in Endocrinology, 2021, 12, 611253.	1.5	6
92	OP0030â€…RANDOMIZED CONTROLLED 24-WEEK TRIAL EVALUATING THE SAFETY AND EFFICACY OF BLINDED TAPERING VERSUS CONTINUATION OF LONG-TERM PREDNISONE (5 MG/D) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB. , 2019, , .		5
93	Exercise and the dipeptidylâ€peptidase IV inhibitor sitagliptin do not improve betaâ€cell function and glucose homeostasis in longâ€lasting type 1 diabetesâ€"A randomised openâ€label study. Endocrinology, Diabetes and Metabolism, 2019, 2, e00075.	1.0	3
94	Designer cytokine for the treatment of diabetes. Nature Metabolism, 2019, 1, 933-934.	5.1	3
95	Predictors of Postprandial Hypoglycemia After Gastric Bypass Surgery: a Retrospective Case-Control Study. Obesity Surgery, 2021, 31, 2497-2502.	1.1	3
96	Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitorâ€"Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153â€"e154. Diabetes Care, 2020, 43, e11-e11.	4.3	2
97	Patient involvement to inform the design of a clinical trial in postbariatric hypoglycaemia. BMC Medical Research Methodology, 2020, 20, 290.	1.4	1
98	OP0086â€…IMPACT OF GLUCOCORTICOID TAPERING ON MARKERS OF BONE METABOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB: EXPLORATORY ANALYIS FROM A RANDOMIZED CONTROLLED TRIAL. , 2019, , .		0
99	Lâ€™inflammation dans la physiopathologie et le traitement du diabÃ¨te de type 2Âet de ses complications. Medecine Des Maladies Metaboliques, 2021, 15, 661-661.	0.1	0
100	SAT-382 Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from the Phase 3/4 SEMIRA Study. Journal of the Endocrine Society, 2019, 3, .	0.1	0
101	SAT-059 Treatment Of Primary Aldosteronism With The mTORC1 Inhibitor Everolimus. Journal of the Endocrine Society, 2019, 3, .	0.1	0
102	SAT-066 Effect Of Interleukin-1-receptor Antagonist On Hemodynamics And Renin-angiotensin-aldosterone System In Obese Individuals. Journal of the Endocrine Society, 2019, 3, .	0.1	0